According to the National Institutes of Health, more than six million Americans, most age 65 or older, may have dementia caused by Alzheimer's disease, a brain disorder known to slowly destroy memory and thinking skills
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
Subscribe To Our Newsletter & Stay Updated
